

SCIENTIFIC MEETING

Dutch Society for Clinical Pharmacology and Biopharmacy
(NVKFB) & Dutch Society for Pharmacology (NVF)

*April 6, 2023 Nijmegen
Experience Center, Radboudumc*

Nederlandse Vereniging voor

KLINISCHE FARMACOLOGIE
en Biofarmacie



PROGRAM

Dear Colleagues,

We would like to welcome you to the NVFKB & NVF scientific meeting on the 6th of April 2023 at the Experience Center of the Radboudumc in Nijmegen.

This year we welcome over 300 participants. The scientific meeting features 10 oral presentations and 75 poster presentations, we hope this will offer a good starting point for enthusiastic discussions.

In addition, an early career development session is organized. Finally, an excellent guest lecture will be given by Prof. Mike Murphy from University of Cambridge.

We hope that you will have a pleasant stay in Nijmegen.

Prof. Dr. Kees Kramers

Chair Dutch Society for Clinical Pharmacology and Biopharmacy

Prof. Dr. Liesbeth de Lange

Chair Dutch Society for Pharmacology

Program **4**

Venue **11**

- 09.00 h** Registration for accreditation (coffee & tea available)
- 09.30 h** **Plenary session** Prof. Mike Murphy, MRC Mitochondrial Biology Unit, University of Cambridge.
Mitochondrial superoxide in ischemia-reperfusion injury
(Auditorium, Experience Center).
Moderators Anton Roks & Guido Krenning
- 10.15 h** Coffee break
- 10.30 h** **Parallel oral presentation sessions** (selected from abstracts) & NVF Satellite Symposium

Session 1 (Waalbrug A) Moderators: Anton Roks & Guido Krenning		Session 2 (Auditorium) Moderators: Alwin Huitema & Robert Rissmann	
10.30	Laurent Chatre ISTCT (CNRS-Université de Caen Normandie) <i>The Reactive Species Interactome-Mitochondria axis in mitochondrial and redox medicine</i>	10.30	Joanneke Overbeek Radboudumc Nijmegen <i>The effect of a reduced dose of Enzalutamide on fatigue and cognition</i>
10.50	Pier Giorgio Mastroberardino Erasmus MC; IFOM ETS - The AIRC Institute of Molecular Oncology, Milano <i>Peripheral and central mitochondrial alterations in neurodegenerative diseases</i>	10.45	Maarten Deenen Catharina Ziekenhuis Eindhoven <i>Frequency and association of NUDT15*3 genetic polymorphism with thiopurine-induced myelosuppression in a Dutch patient population with Inflammatory Bowel Disease</i>
11.10	Tingting Chen University Medical Center Groningen <i>Mitochondrial transplantation, as a novel neuroprotective approach in ferroptosis</i>	11.00	Maud van der Kleij Netherlands Cancer Institute/ Erasmus MC <i>A prospective study on therapeutic drug monitoring or oral targeted therapies in oncology – updated results</i>
11.25	Guido Krenning University Medical Center Groningen, Sulfateq BV <i>Development of SUL compounds</i>	11.15	Meichun Gao VU Amsterdam <i>Pharmacological characterization of photocaged Histamine H3 and H4 receptor agonists</i>
11.45	Annika Jüttner Erasmus MC Rotterdam <i>Vascular and renal effects of SUL compounds in a model of endothelial aging</i>	11.30	Mendy Boersma-ter Avest Radboudumc Nijmegen <i>Model-informed precision dosing of Eculizumab in patients with Paroxysmal Nocturnal Hemoglobinuria</i>
		11.45	Robert Flint Erasmusmc <i>Oral and intravenous Amoxicillin dosing recommendations in neonates at risk for possible severe bacterial infections: a pooled population pharmacokinetic study</i>

12.00 h **Grab your lunch and go to:**

12.00 h General Meetings, NVKFB (Auditorium),
NVF (Waalbrug A) during
or

12.15 h junior early career session (De Oversteek)
Career paths discussion pt1, Guido Krenning and Caitrin Crudden
Moderators: Desislava Nesheva, Claudia Perez
Here the audience, and especially early-career investigators, will have the opportunity to ask questions about career progression and career paths in and outside of academia. This is an interactive session in a relaxed format lead by four panelists in total with different scientific careers including both industry and academia.

13.00 h Moderated poster sessions (Experience Center)

PITCH SESSION 1, General – Education			
Moderators: Noortje Swart & Teun van Gelder			
Nr.	HRS	PRESENTER	ABSTRACT TITLE
1	13.00	Annette van der Vossen	CLINICALLY RELEVANT PHARMACOKINETIC INTERACTION OF CLOZAPINE AND TOPIRAMATE THROUGH CYP3A4 INDUCTION
2	13.05	Elise Smolders	EXPOSURE OF IMATINIB USING DIFFERENT FORMULATIONS FOR THE TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
3	13.10	Erik Donker	THE EUROPEAN PRESCRIBING EXAM: A QUALITY ANALYSIS OF THE FIRST CROSS-BORDER ESTABLISHED PHARMACOTHERAPY ASSESSMENT FOR FINAL YEAR MEDICAL STUDENTS
4	13.15	Erik Donker	THE IMPACT OF A SUMMATIVE NATIONAL PRESCRIBING ASSESSMENT AND CURRICULUM TYPE ON THE DEVELOPMENT OF THE PRESCRIBING COMPETENCE OF JUNIOR DOCTORS
5	13.20	Heleen van der Sijs	A FRAMEWORK FOR CLINICAL PHARMACEUTICAL REASONING
6	13.25	Lieke Mitrov-Winkelmolen	DIGIFAB® AND FREE DIGOXIN ELIMINATION IN A PATIENT WITH A COMBINED DIGOXIN/METFORMIN INTOXICATION ON CVVHD
7	13.30	Mariëlle Hartjes	UNDERSTANDING THERAPEUTIC REASONING: INSIGHTS FROM COGNITIVE PSYCHOLOGY
8	13.35	Sophie Wassenaar	DURATION OF IMMUNO-ASSAY INTERFERENCE IN METHOTREXATE-LEVELS AFTER GLUCARPIDASE ADMINISTRATION FOLLOWING HIGH-DOSE METHOTREXATE THERAPY
9	13.40	Stephanie van der Wouden	DEVELOPMENT OF AN E-LEARNING TO IMPLEMENT THE NEW ADDENDUM IN THE GUIDELINE POLYPHARMACY IN ELDERLY

PITCH SESSION 2, General			
Moderators: Kees Kramers & Mendy Boersma-ter Avest			
Nr.	HRS	PRESENTER	ABSTRACT TITLE
1	13.00	Anton Urbach	IDENTIFYING REQUIREMENTS OF DUTCH PRIMARY CARE PHARMACISTS AND GENERAL PRACTITIONERS FOR THE DEVELOPMENT OF TELEPHARMACOLOGY
2	13.05	Boukje Eveleens Maarse	A RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE ON ORAL CHOLERA VACCINATION WITH INTRANASAL RECHALLENGE AS ADAPTIVE IMMUNE CHALLENGE MODEL
3	13.10	Emma de Ruiter	THE ROLE OF ELECTRONIC PRESCRIBING SYSTEMS IN THE MANAGEMENT OF ADVERSE DRUG REACTIONS TO BIOLOGICALS
4	13.15	Francisca van den Oever	ALGORITHM-MANAGED DOSING AND PHARMACIST-MANAGED DOSING OF ERYTHROPOIETIN STIMULATING AGENTS IN RENAL ANEMIA: A SYSTEMATIC REVIEW
5	13.20	Julia Cybulska	CHARACTERISTICS OF POLYPSYCHOPHARMACY PATIENTS IN PRIMARY CARE
6	13.25	Jurjen Kingma	QUALITY OF REGISTRATION OF THE CONTRAINDICATIONS MORBID OBESITY AND BARIATRIC SURGERY AND THE EFFECT ON THE NUMBER OF DRUG RELATED PROBLEMS
7	13.30	Merel Janssen	PRESCRIPTIONS OF NEWER GLUCOSE REGULATING AGENTS IN OLDER HOSPITALIZED PATIENTS WITH TYPE 2 DIABETES
8	13.35	Nikki Werkman	THE USE OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS OR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS VERSUS SULFONYLUREAS AND THE RISK OF LOWER LIMB AMPUTATIONS
9.	13.40	Tessa Bosch	DOSE OPTIMIZATION BY A CLINICAL DECISION SUPPORT SYSTEM OF VANCOMYCIN IN (MORBID) OBESE PATIENTS
10	13.45	Esther Karssemeijer	INVESTIGATING THE ROLE OF CLASSES OF ANTIHYPERTENSIVE DRUGS ON BLOOD PRESSURE VARIABILITY

PITCH SESSION 3, Oncology			
Moderators: Ron Mathijssen & Berdien Oortgiesen			
Nr.	HRS	PRESENTER	ABSTRACT TITLE
1	13.00	Daniel Souwer	TAMOXIFEN PHARMACOKINETICS AND PHARMACODYNAMICS IN OLDER PATIENTS WITH NON-METASTATIC BREAST CANCER
2	13.05	Vincent van de Vlasakker	DETERMINING THE ABSOLUTE BIOAVAILABILITY OF OXALIPLATIN FOLLOWING INTRAPERITONEAL ADMINISTRATION BY PRESSURIZED INTRAPERITONEAL AEROSOL CHEMOTHERAPY
3	13.10	Elly van der Veen	PRECLINICAL DEVELOPMENT AND CLINICAL PHARMACOLOGY OF 89ZR-PEMBROLIZUMAB
4	13.15	Leila-Sophie Otten	PROGNOSTIC VALUE OF NIVOLUMAB CLEARANCE IN NON-SMALL CELL LUNG CANCER PATIENTS TO ASSESS NON-RESPONSE EARLY IN TREATMENT
5	13.20	Lisa van der Heijden	DIFFERENTIAL CYP3A ACTIVITY IN PATIENTS WITH METASTATIC PROSTATE CANCER AND OTHER SOLID TUMOURS: AN IN VIVO PHENOTYPING STUDY WITH MIDAZOLAM
6	13.25	Loek de Jong	SYSTEMIC EXPOSURE TO CISPLATIN AND PACLITAXEL AFTER INTRAPERITONEAL CHEMOTHERAPY IN OVARIAN CANCER
7	13.30	Lourens Bloem	EUROPEAN CONDITIONAL MARKETING AUTHORIZATION IN A RAPIDLY EVOLVING TREATMENT LANDSCAPE: A COMPREHENSIVE STUDY OF ANTICANCER MEDICINAL PRODUCTS IN 2006-2020
8	13.35	Maida Mohamed Ali	EXPOSURE-RESPONSE ANALYSES OF OLAPARIB IN REAL-LIFE PATIENTS WITH OVARIAN AND BREAST CANCER.
9	13.40	Sanne Buijs	INFLUENCE OF CANNABIDIOL (CBD) ON TAMOXIFEN PHARMACOKINETICS IN PATIENTS WITH PRIMARY BREAST CANCER AND TAMOXIFEN-RELATED SIDE EFFECTS
10.	13.45	Elise Smolders Helle-Brit Fiebrich Westra	SUSTAINABILITY INITIATIVE: DOSE BANDING OF PACLITAXEL TO MINIMIZE DRUG WASTE

PITCH SESSION 4, Pediatrics			
Moderators: Karel Allegaert & Carina Bethlehem			
Nr.	HRS	PRESENTER	ABSTRACT TITLE
1	13.00	Franciska van den Oever	LIMITED PHARMACEUTICAL LITERACY IN PATIENTS ON HEMODIALYSIS IN THE NETHERLANDS AS ASSESSED WITH THE RALPH INTERVIEW GUIDE
2	13.05	Julia Möhlmann	ADMETTRE MTX-STUDY: ADHERENCE TO LOW-DOSE METHOTREXATE IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS USING A SENSITIVE METHOTREXATE ASSAY
3	13.10	Kajie Liang	RISPERIDONE-INDUCED WEIGHT GAIN AND ALTERATIONS IN APPETITE HORMONES IN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDER
4	13.15	Karel Allegaert	THE QTC INTERVAL IN FORMER VERY PRETERM INFANTS IN ADOLESCENCE AND YOUNG ADULTHOOD IS NOT DIFFERENT FROM TERM-BORN CONTROLS
5	13.20	Marc Sylva	SERUM IVABRADINE ASSOCIATES WITH HEART RATE REDUCTION BUT ENTERAL EXPOSURE IS UNPREDICTABLE IN POST-SURGICAL JET
6	13.25	Marika de Hoop-Sommen	DO INFANTS NEED A TWO TIMES HIGHER GENTAMICIN DOSE THAN NEONATES? A PBPK DOSE-FINDING STUDY
7	13.30	Rebecca Hermans	THERAPEUTIC DRUG MONITORING OF ANTIPSYCHOTIC DRUGS IN CHILDREN AND ADOLESCENTS: THE INTERNATIONAL MULTICENTRE SPACE 2: STAR RANDOMISED CONTROLLED TRIAL PROTOCOL
8	13.35	Rebecca Hermans	OPTIMISING RISPERIDONE TREATMENT IN CHILDREN WITH AUTISM SPECTRUM DISORDER: A THERAPEUTIC DRUG MONITORING SIMULATION STUDY
9	13.40	Wala al Arashi	DESMPRESSIN TO PREVENT AND TREAT BLEEDING IN PREGNANT WOMEN WITH INHERITED BLEEDING DISORDER: A SYSTEMATIC LITERATURE REVIEW

PITCH SESSION 5, PK/TDM			
Moderators: Niels Vos & Catherijne Knibbe			
Nr.	HRS	PRESENTER	ABSTRACT TITLE
1	13.00	Aernout van Haarst	THE EFFECT OF NASAL CONGESTION ON THE BIOAVAILABILITY OF INTRANASALLY ADMINISTERED EPINEPHRINE IN HEALTHY ADULT SUBJECTS WITH SEASONAL ALLERGIES
2	13.05	Joost van Mechelen	RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE PHARMACODYNAMICS AND PHARMACOKINETICS OF ORAL AND INTRAVENOUS S-KETAMINE IN HEALTHY VOLUNTEERS
3	13.10	Julia van Dommelen	VARIABILITY IN WHOLE BLOOD TACROLIMUS CONCENTRATIONS AFTER ORAL AND CONTINUOUS INTRAVENOUS ADMINISTRATION EARLY POST-LUNG TRANSPLANTATION
4	13.15	Maartje van de Meeberg	A HIGHER RED BLOOD CELL METHOTREXATE POLYGLUTAMATE 3 CONCENTRATION IS ASSOCIATED WITH AN INCREASED METHOTREXATE DRUG-SURVIVAL IN PATIENTS WITH CROHN'S DISEASE
5	13.20	Merve Sivridas	THERAPEUTIC DRUG MONITORING OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS DURING MAINTENANCE TREATMENT – TUMMY STUDY
6	13.25	Rebecca Verheggen	THE CLINICAL IMPACT OF THE DRUG-DRUG INTERACTION BETWEEN CYCLOSPORINE AND LETERMIVIR IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
7	13.30	Wendy van der Wekken	LOWER EXPOSURE TO BICTEGRAVIR IN THIRD TRIMESTER IN PREGNANT WOMEN LIVING WITH HIV

PITCH SESSION 6, PK modelling

Moderators: Marjolijn Lub-de Hooge & Robert Rissmann

Nr.	HRS	PRESENTER	ABSTRACT TITLE
1	13.00	Damian Roelofsen	EXPOSURE ESTIMATION IN A NEXT GENERATION RISK ASSESSMENT CONTEXT: USING BEWO B30 CELLS TO STUDY TRANSPLACENTAL PASSAGE OF DRUGS AND CHEMICALS
2	13.05	Eva Streekstra	INTESTINAL TISSUE ORGANOIDs TO STUDY DRUG TRANSPORT AND METABOLISM IN VARIOUS AGE GROUPS
3	13.10	Hedwig van Hove	ASSESSING THE PLACENTAL TRANSFER OF SOTALOL VIA EX VIVO HUMAN PLACENTA PERFUSIONS: A STEP-UP TOWARDS MODEL-INDFORMED DRUG DOSING IN PREGNANCY
4	13.15	Joyce van der Heijden	OPTIMIZING PRE-NATAL BETAMETHASONE DOSING TO PREVENT FOETAL RESPIRATORY DISTRESS SYNDROME: A COMBINED PLACENTA PERFUSION AND PREGNANCY PBPK MODELLING APPROACH
5	13.20	Michael Cloesmeijer	PHARMACOKINETIC-PHARMACODYNAMIC MODELLING IN HEMOPHILIA A: RELATING THROMBIN AND PLASMIN GENERATION TO FACTOR VIII ACTIVITY AFTER ADMINISTRATION OF VWF/ FVIII
6	13.25	Paul Bank	QUANTIFYING THE EFFECT OF METHOTREXATE ON THE ADALIMUMAB RESPONSE IN PSORIASIS BY PHARMACOKINETIC-PHARMACODYNAMIC MODELLING
7	13.30	Sam Schoenmakers	PREECLAMPSIA INCREASES MATERNAL EXPOSURE TO BETAMETHASONE IN PREGNANCY: A POPULATION PHARMACOKINETIC STUDY
8	13.35	Tan Zhang	MODEL-BASED DOSING RECOMMENDATIONS FOR VANCOMYCIN IN HOSPITALIZED PATIENTS WITH VARYING DEGREES OF OBESITY AND RENAL (DYS)FUNCTION
9	13.40	Tim Preijers	DOSING OF CONVALESCENT PLASMA AND HYPERIMMUNE ANTI-SARS-COV-2 IMMUNOGLOBULINES: A PHASE I/II DOSE FINDING STUDY
10	13.45	Zhiyuan Tan	CABOZANTINIB POPULATION PHARMACOKINETICS IN METASTATIC RENAL CELL CARCINOMA PATIENTS: TOWARDS DRUG EXPENSE SAVING REGIMENS

PITCH SESSION 7, Preclin 1

Moderators: Rick Greupink & Martina Schmidt

Nr.	HRS	PRESENTER	ABSTRACT TITLE
1	13.00	Claudia Perez Almeria	CXCR4 OLIGOMERIZATION: DETECTION, MODULATION AND FUNCTIONAL CONSEQUENCES
2	13.05	Ivana Josimovic	PHARMACOLOGICAL CHARACTERIZATION OF H1R AND H3R SMALL MOLECULE PHOTOLIGANDS – REACHING BEYOND THE UV SPECTRUM
3	13.10	Justyna Adamska	PHOTOSWITCHABLE SMALL-MOLECULE LIGANDS TO OPTICALLY MODULATE CHEMOKINE RECEPTORS
4	13.15	Lianne Stevens	NOVEL EXPLANTED HUMAN LIVER MODEL TO ASSESS HEPATIC EXTRACTION, BILIARY EXCRETION AND TRANSPORTER FUNCTION
5	13.20	Noor Verhagen	THE ROLE OF ABC TRANSPORTERS IN TYROSINE KINASE INHIBITOR TREATMENT OF CHRONIC MYELOID LEUKEMIA PATIENTS
6	13.25	Noraly Jonis	NOVEL INSIGHTS INTO THE INTERACTION BETWEEN BCRP AND ANTIBIOTICS IN DIFFERENT SPECIES
7	13.30	Tamara Mocking	LABEL-FREE DETECTION OF PROSTAGLANDIN TRANSPORTER (SLCO2A1) ACTIVITY USING A TRACT ASSAY
8	13.35	Tiffany van der Meer	PHOTOSWITCHABLE ANALOGUES OF THE PDE5 INHIBITOR SILDENAFIL
9	13.40	Yuequ Zhang	ACTIVATION OF SK CHANNELS FACILITATES HUMAN NEURONAL DIFFERENTIATION

PITCH SESSION 8, moderators Annika Jüttner & Matthijs Blanckesteijn			
Nr.	HRS	PRESENTER	ABSTRACT TITLE
2	13.00	Desislava Nesheva	INACTIVATION OF THE ACKR3 BY A SMALL-MOLECULE INVERSE AGONIST
3	13.05	Eva Pfeil	HCMV-ENCODED VIRAL GPCR US28 SIGNALS TO THE HIPPO PATHWAY VIA Gq/11
4	13.10	Hong Yan	AIR POLLUTION PARTICLES ACCELERATE RSL-3-INDUCED FERROPTOSIS IN HT22 CELLS VIA CAMP-EPAC1 PATHWAY
5	13.15	Hsiao-Tzu Chien	RE-EVALUATING THE NEED FOR CHRONIC TOXICITY STUDIES WITH THERAPEUTIC MONOCLONAL ANTIBODIES, USING A WEIGHT-OF-EVIDENCE APPROACH
6	13.20	Ivan Maria Smoday, instead of Luka Kalogjera	PERIPHERAL AND CENTRAL VASCULAR FUNCTION ALTERATIONS CAUSED BY UNILATERAL ADRENALECTOMY IN RATS AND EFFECTS OF BPC 157 PENTADECAPETIDE
7	13.25	Soroush Mohammadi Jouabadi	KILLING ME UNSOFTLY: COLCHICINE A POTENTIAL SAVIOR OF ARTERIAL STIFFNESS
8	13.30	Yang Luo	THIOSULFATE SULFURTRANSFERASE DEFICIENCY PROMOTES CEREBRAL CORTICAL OXIDATIVE DISTRESS RESULTING IN ANTIOXIDANT SYSTEM DYSFUNCTION
9	13.35	Annika Jüttner	SUL138 SUPPORT OF MITOCHONDRIAL FUNCTION PRECLUDES VASCULAR AND KIDNEY DYSFUNCTION IN A MOUSE MODEL OF ENDOTHELIAL-SPECIFIC AGING

14.00 h NVKFB-Thesis Award (by Robert Rissmann) & NVF-Thesis Awards (2 Van Zwieten awards by Martina Schmidt)

14.30 h Early career development for junior investigators (Auditorium)
 Career paths discussion pt2 with Mike Murphy and Azra Mujic-Delic
 Moderators: Desislava Nesheva, Claudia Perez
 Here the audience, and especially early-career investigators, will have the opportunity to ask questions about career progression and career paths in and outside of academia. This is an interactive session in a relaxed format lead by four panelists in total with different scientific careers including both industry and academia.

15.15 h Break

15.30 h Prize ceremony with pitches by winners (Auditorium)
 NVKFB-TOP Publication Award 2021
 NVKFB Top Publication Award 2022
 NVKFB-Education Award
 NVF' best poster prize
 NVKFB' best poster prize

15.45 h Selected abstracts (Auditorium)

<i>Moderators: Alwin Huitema & Robert Rissmann</i>	
15.45 h	Thomas Knuijver Radboudumc/Iriszorg <i>Linking pharmacokinetics of Ibogaine and its metabolites with cardiac and cerebellar side effects and effects on withdrawal in detoxifying Opioid use disorder patients</i>
16.00 h	Tessa Jaspers ETZ <i>Smaller Nadroparin dose reductions required for patients with renal impairment: a multicentre study.</i>
16.15 h	Tim Somers Radboudumc <i>Statins interfere with cardiomyocyte mitochondrial function and intracellular acidification</i>
16.30 h	Wouter Bakker CHDR <i>A randomized, double-blind, double-dummy, placebo controlled, four-way cross-over study to investigate the analgesic effects and CNS effects on Morphine and Pregabalin in healthy subjects.</i>

16.45 h Drinks and networking

Experience Center Radboudumc

Address

Geert Grooteplein Noord 15
6525 EZ NIJMEGEN

The experience center is located near the hospital's main entrance and visitor parking near the entrance.

Arriving by train (Nijmegen Central Station)

Bus 6 (platform L), 10 (platform M), to Bus stop Radboud university medical center (8 minutes)

Public transport [link](#).

Arriving by car

You can park your car in the garage at the main entrance 24 hours a day. You can pay with debit card.

